LXRX catalyst calendar

LEXICON PHARMACEUTICALS, INC.

Upcoming catalysts
2
Cash runway
38.8 months
Cash & investments
$191M
Phase 3 programs
15

LEXICON PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 29, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 38.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 59 concluded trials, 93% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 29, 2026 est. Next quarterly earnings (projected) Earnings —
January 15, 2027 A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy Trial Milestone Phase 3

Track LXRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open LXRX in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
May 7, 2026 Quarterly results filed (8-K) Earnings —
May 6, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
April 30, 2026 8-K filed: Material agreement Corporate —
March 5, 2026 Quarterly results filed (8-K) Earnings —
February 2, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
January 29, 2026 Quarterly results filed (8-K) Earnings —
November 10, 2025 8-K filed: Other event Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
November 6, 2025 8-K filed: Other event Filing —
August 6, 2025 Quarterly results filed (8-K) Earnings —
July 28, 2025 8-K filed: Other event Filing —
July 3, 2025 8-K filed: Other event Filing —
June 3, 2025 8-K filed: Material agreement Corporate —
May 13, 2025 Quarterly results filed (8-K) Earnings —
January 14, 2025 A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Trial Milestone Phase 2
November 18, 2022 Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia Trial Milestone Phase 2
May 23, 2022 Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain Trial Milestone Phase 2
July 8, 2020 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk Trial Milestone Phase 3
June 5, 2020 Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) Trial Milestone Phase 3
September 17, 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents Trial Milestone Phase 3
August 17, 2019 Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure Trial Milestone Phase 2
August 6, 2019 Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy Trial Milestone Phase 3
May 22, 2019 Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Trial Milestone Phase 3
May 16, 2019 A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control Trial Milestone Phase 3
May 16, 2019 Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin Trial Milestone Phase 3
April 22, 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy Trial Milestone Phase 3
April 17, 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin Trial Milestone Phase 3
March 25, 2019 Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control Trial Milestone Phase 3
February 26, 2019 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.